The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p)

Gene Therapy

Volumn 13, Issue 12, 2006, Pages 986-990

  Shen, B H ^a,b   Bauzon, M ^a   Hermiston, Terry W ^a  

^a BAYER AG   (Germany)

^b WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

Ad11p; Ad3; Ad5; Cancer; Group B adenovirus; Hypoxia; Oncolytic virus; Replication selective Ad

Indexed keywords

E1A PROTEIN; MEMBRANE COFACTOR PROTEIN; VIRUS DNA; VIRUS RECEPTOR; VIRUS VECTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESEARCH; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL HYPOXIA; CELL VIABILITY; CYTOLYSIS; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN ADENOVIRUS; IN VITRO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTYPE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ANOXIA; ANTIGENS, CD46; CYTOPATHOGENIC EFFECT, VIRAL; FLOW CYTOMETRY; GENE THERAPY; GENOTYPE; HEMATOLOGIC NEOPLASMS; HUMANS; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 3;

EID: 33744808553     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302736     Document Type: Article

References (32)

1. Clark KR, Johnson PR. Gene delivery of vaccines for infectious disease. Curr Opin Mol Ther 2001; 3: 375-384.
2. Horowitz J. Adenovirus-mediated p53 gene therapy: Overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1999; 1: 500-509.
3. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 2001; 1: 101-122.
4. Dobbelstein M. Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol 2004; 273: 291-334.
5. Kirn D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
6. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, EIBash M, Lanuti M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9: 2121-2133.
7. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357.
8. Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
9. Jee YS, Lee SG, Lee JC, Kim MJ, Lee JJ, Kim DY et al. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 2002; 22: 2629-2634.
10. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V et al. Expression of the coxsackie adenovius receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res 2002; 62: 3812-3818.
11. Zeimet AG, Mulls Holzner E, Schuler A, Hartung G, Berger J, Hermann M et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Therapy 2002; 9: 1093-1100.
12. Turturro F. Recombinant adenovirus-mediated cytotoxic gene therapy of lymphoproliferative disorders: Is CAR important for the vector to ride? Gene Therapy 2003; 10: 100-104.
13. You Z, Fischer DC, Tong X, Hasenburg A, Aguilar-Cordova E, Kieback DG. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and trangene expression. Cancer Gene Ther 2001; 8: 168-175.
14. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: Low seroprevalence and non-cross-reactivity with Ad5. J Virol 2004; 78: 13207-13215.
15. Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M et al. Development of adenovirus serotype 35 as a gene transfer vector. Virology 2003; 311: 384-393.
16. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, Lieber A et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004; 6: 631-641.
17. Gao W, Robbins PD, Gambotto A. Human adenovirus type 35: Nucleotide sequence and vector development. Gene Therapy 2003; 10: 1941-1949.
18. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271.
19. Sakurai F, Mizuguchi H, Yamaguchi T, Hayakawa T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol Ther 2003; 8: 813-821.
20. Roelvink PW, Lisonova A, Lee JG, Li Y, Bergelson JM, Finberg RW et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909-7915.
21. Mei YF, Lindman K, Wadell G. Two closely related adenovirus genome types with kidney or respiratory tract tropism differ in their binding to epithelial cells of various origins. Virology 1998; 240: 254-266.
22. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
23. Sirena D, Lilienfeld B, Eisenhut M, Kahn S, Boucke K, Beerli RR et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004; 78: 4454-4462.
24. Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G, Arnberg N. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 2003; 77: 9183-9191.
25. Fishelson Z, Donin N, Zell S, Schultz S, Kiuschfink M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40: 109-123.
26. Pipiya T, Sauthoff H, Huang YQ, Cheng B, Cheng J, Heitner S et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Therapy 2005; 12: 911-917.
27. Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, trans gene expression and replication. Gene Therapy 2005; 12: 902-910.
28. Segerman A, Arnberg N, Erikson A, Lindman K, Wadell G. There are two different species B adenovirus receptors: SBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J Virol 2003; 77: 1157-1162.
29. Shayakhmetov DM, Eberly AM, Li ZY, Lieber A. Deletion of penton RGD motifs affects the efficiency of both the internalization and the endosome escape of viral particles containing adenovirus serotype 5 or 35 fiber knobs. J Virol 2005; 79: 1053-1061.
30. Cho WK, Seong YR, Lee YH, Kim MJ, Hwang KS, Yoo J et al. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol Ther 2004; 10: 938-949.
31. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004, 10: 8603-8612.
32. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22: 2065-2072.